Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Hace 1 día · Ismayl M, Machanahalli Balakrishna A, et al. Meta-Analysis Comparing Catheter-Directed Thrombolysis Versus Systemic Anticoagulation Alone for Submassive Pulmonary Embolism. Am J Cardiol. 2022;178:154-162. 20. Kuo WT, Banerjee A, Kim PS, et al. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT).

  2. Hace 1 día · Clin Appl Thromb Hemost. 2022;28: 10760296221140114. doi: 10.1177/10760296221140114. 5. Zaazoue KA, ElBoraey MA, Core J, et al. Percutaneous mechanical thrombectomy as primary therapy for high-risk pulmonary embolism in patients with absolute contraindications to anticoagulation.

  3. Hace 1 día · Immediate cardiopulmonary responses to consecutive pulmonary embolism: a randomized, controlled, experimental study. Acute pulmonary embolism (PE) induces ventilation-perfusion mismatch and hypoxia and increases pulmonary pressure and right ventricular (RV) afterload, entailing potentially fatal RV failure within a short tim...

  4. Hace 1 día · This contrasts with 55.9% of non-COVID PE patients who were also on anticoagulants. Alarmingly, the study found that COVID-19 patients on anticoagulation had a 10.5% risk of bleeding compared to just 2.1% in their non-COVID counterparts. The adjusted odds ratio for bleeding in these patients was 4.75, indicating a significantly higher risk.

  5. Hace 4 días · DOI: 10.1007/s11239-024-02998-9 Corpus ID: 269898931; Optimal hemodynamic parameters for risk stratification in acute pulmonary embolism patients. @article{Zuin2024OptimalHP, title={Optimal hemodynamic parameters for risk stratification in acute pulmonary embolism patients.}, author={Marco Zuin and Stanislav Henkin and Eileen M Harder and Gregory Piazza}, journal={Journal of thrombosis and ...

  6. Hace 13 horas · Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently investigating the use of Apixaban in underweight patients, with some results suggesting altered pharmacokinetics, decreased drug absorption, and potential overdosing in this population. This study examined the ...

  7. Hace 3 días · The BIO-CONDUCT study consented 194 patients at 14 U.S. centers from December 12, 2022 through September 22, 2023. Eight patients exited prior to LBBAP implant attempt as screen failures ( Figure 1 ).